Primary Care Migraine© Diagnosis, Secondary Headache, Acute Therapy, Prevention
Primary Care Migraine© is a free web and app-based training program that provides primary care professionals with continuing medical education (CME) credits while learning about the most cutting-edge treatments and preventative protocols for migraine disease. This activity includes four video-based modules.
Primary Care Migraine© CME Modules
MODULE 1: The Diagnosis of Migraine in Primary Care
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss the epidemiology of migraine both within the population, but also as it relates to patients seen in your primary care offices
- Recognize the under-diagnosis of migraine
- Apply the diagnostic criteria for migraine
- Use abbreviated tools to help simplify the diagnosis of migraine in your practice
- Develop a general approach to the diagnosis of migraine and other headache disorder
MODULE 2: Secondary Headache Disorders in Primary Care
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Recognize the Red Flags that suggest a secondary headache disorder
- Order the appropriate imaging test to help diagnose headache
- Recommend a lumbar puncture when indicated by headache signs and symptoms and interpret findings
MODULE 3: ABCs of Acute Therapy in Primary Care
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Define acute medication use
- Discuss their mechanisms of action
- Set realistic goals for therapy
- Discuss the different types of acute therapies
- Review common side effects and cautions with their use
MODULE 4: ABCs of Preventive Therapy in Primary Care
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Define preventive therapy treatments for migraine
- Review preventive treatment indications
- Identify the medication classes used for migraine prevention
Acknowledgement of Commercial Support
This activity is supported by educational grants from Amgen, Biohaven Pharmaceuticals, and Lilly.